Top

International Journal of Colorectal Disease

Published in:

01-11-2020 | Metformin | Original Article

Relationship between metformin therapy and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis

Authors: Wen-Tao Yang, Hao-Jie Yang, Jian-Guo Zhou, Jia-Le Liu

Published in: International Journal of Colorectal Disease | Issue 11/2020

Abstract

Objective

At present, there are many studies on metformin and the risk of colorectal cancer in patients with diabetes, but the conclusions are contradictory. Our aim is to comprehensively collect the published literature and systematically evaluate the relationship between metformin and the risk of colorectal cancer in patients with diabetes.

Methods

We systematically searched the MEDLINE, EMBASE, and CENTRAL databases up to March 2020. We adopted adjusted estimates and their 95% confidence intervals (CI) to calculate summary effect estimates using either a fixed-effects or a random-effects model.

Results

A total of 17 articles were included in this study, with a total of 1,092,074 patients with diabetes. Meta-analysis of observational studies showed that metformin treatment could significantly reduce the incidence of colorectal cancer in diabetic patients (adjusted RR = 0.884, 95%CI = 0.829–0.943), and there was heterogeneity between studies (p = 0.013, I² = 47.9%). Subgroup analysis showed that metformin treatment was significantly associated with a significantly reduced risk of colorectal cancer in diabetics in America and Europe (adjusted RR = 0.852, 95%CI = 0.786–0.924; adjusted RR = 0.900, 95%CI = 0.845–0.958). Patients with diabetes treated with metformin had a significantly lower risk of colorectal cancer compared with patients who had never been treated with metformin or sulfonamide monotherapy (adjusted RR = 0.863, 95%CI = 0.776–0.960; adjusted RR = 0.911, 95%CI = 0.882–0.941).

Conclusions

Metformin therapy is associated with a significantly reduced risk of colorectal disease in patients with diabetes, and it is necessary to conduct larger, more standardized clinical studies to verify this conclusion.

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin. 69(1):7–34. https://doi.org/10.3322/caac.21551CrossRefPubMed

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science. 339(6127):1546–1558. https://doi.org/10.1126/science.1235122CrossRefPubMedPubMedCentral

Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD (2012) Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 366(8):687–696. https://doi.org/10.1056/NEJMoa1100370CrossRefPubMedPubMedCentral

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. Diabetes Care. 33(7):1674–1685. https://doi.org/10.2337/dc10-0666CrossRefPubMedPubMedCentral

Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 52(9):1766–1777. https://doi.org/10.1007/s00125-009-1440-6CrossRefPubMed

Gallagher EJ, LeRoith D (2011) Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci. 1243:54–68. https://doi.org/10.1111/j.1749-6632.2011.06285.xCrossRefPubMed

Liu F, Yan L, Wang Z, Lu Y, Chu Y, Li X et al (2017) Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis. Oncotarget 8(9):16017–16026. https://doi.org/10.18632/oncotarget.13762CrossRefPubMed

Wells GA, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

Deng M, Lei S, Huang D, Wang H, Xia S, Xu E, Wu Y, Zhang H (2020) Suppressive effects of metformin on colorectal adenoma incidence and malignant progression. Pathol Res Pract. 216(2):152775. https://doi.org/10.1016/j.prp.2019.152775CrossRefPubMed

10.

Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 343:d5928. https://doi.org/10.1136/bmj.d5928CrossRefPubMedPubMedCentral

11.

Greenland S (1987) Quantitative Methods in the Review of Epidemiologic Literature. Epidemiol Rev 9:1–30. https://doi.org/10.1093/oxfordjournals.epirev.a036298CrossRefPubMed

12.

Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med. 127(9):820–826. https://doi.org/10.7326/0003-4819-127-9-199711010-00008CrossRefPubMed

13.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med. 21(11):1539–1558. https://doi.org/10.1002/sim.1186CrossRefPubMed

14.

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22(4):719–748PubMed

15.

DerSimonian R, Laird N (2015) Meta-analysis in clinical trials revisited. Contemp Clin Trials 45(Pt A):139–145. https://doi.org/10.1016/j.cct.2015.09.002CrossRefPubMedPubMedCentral

16.

Thompson SG (1994) Why sources of heterogeneity in meta-analysis should be investigated. BMJ. 309(6965):1351–1355. https://doi.org/10.1136/bmj.309.6965.1351CrossRefPubMedPubMedCentral

17.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics. 50(4):1088–1101CrossRefPubMed

18.

Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ. 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629CrossRefPubMedPubMedCentral

19.

Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR (1991) Publication bias in clinical research. Lancet. 337(8746):867–872. https://doi.org/10.1016/0140-6736(91)90201-yCrossRefPubMed

20.

Kowall B, Stang A, Rathmann W, Kostev K (2015) No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiol Drug Saf. 24(8):865–874. https://doi.org/10.1002/pds.3823CrossRefPubMed

21.

Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, Doi SA (2014) Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev. 23(2):134–140. https://doi.org/10.1097/CEJ.0b013e3283656394CrossRefPubMed

22.

Lee MS, Hsu CC, Wahlqvist ML, Tsai H (2011) N., Chang YH, Huang YC. Type 2 Diabetes Increases and Metformin Reduces Total, Colorectal, Liver and Pancreatic Cancer Incidences in Taiwanese: A Representative Population Prospective Cohort Study of 800,000 Individuals. BMC cancer. 11:20. https://doi.org/10.1186/1471-2407-11-20CrossRefPubMedPubMedCentral

23.

Wang SY, Chuang CS, Muo CH, Tu ST, Lin MC, Sung FC, Kao CH (2013) Metformin and the incidence of cancer in patients with diabetes: a nested case-control study. Diabetes Care. 36(9):e155–e156. https://doi.org/10.2337/dc13-0708CrossRefPubMedPubMedCentral

24.

Tseng CH (2017) Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis. Diabetes Metab. 43(5):438–445. https://doi.org/10.1016/j.diabet.2017.03.004CrossRefPubMed

25.

Tseng CH (2012) Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur J Endocrinol. 167(3):409–416. https://doi.org/10.1530/EJE-12-0369CrossRefPubMed

26.

Lin CM, Huang HL, Chu FY, Fan HC, Chen HA, Chu DM, Wu LW, Wang CC, Chen WL, Lin SH, Ho SY (2015) Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study. PLoS One. 10(5):e0125421. https://doi.org/10.1371/journal.pone.0125421CrossRefPubMedPubMedCentral

27.

Chang YT, Tsai HL, Kung YT, Yeh YS, Huang CW, Ma CJ, Chiu HC, Wang JY (2018) Dose-Dependent Relationship Between Metformin and Colorectal Cancer Occurrence Among Patients with Type 2 Diabetes-A Nationwide Cohort Study. Transl Oncol. 11(2):535–541. https://doi.org/10.1016/j.tranon.2018.02.012CrossRefPubMedPubMedCentral

28.

Ferrara A, Lewis JD, Quesenberry CP Jr, Peng T, Strom BL, Van Den Eeden SK et al (2011) Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 34(4):923–929. https://doi.org/10.2337/dc10-1067CrossRefPubMedPubMedCentral

29.

Bradley MC, Ferrara A, Achacoso N, Ehrlich SF, Quesenberry CP Jr, Habel LA (2018) A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus. Cancer Epidemiol Biomarkers Prev. 27(5):525–530. https://doi.org/10.1158/1055-9965.EPI-17-0424CrossRefPubMedPubMedCentral

30.

Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, Sacerdote C, Ashby D, Vineis P, Tzoulaki I, Ioannidis JPA (2014) Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intention-To-Treat Trial. Diabetes care. 37(9):2522–2532. https://doi.org/10.2337/dc14-0584CrossRefPubMed

31.

Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S (2013) The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 22(10):1877–1883. https://doi.org/10.1158/1055-9965.EPI-13-0196CrossRefPubMed

32.

Farmer RE, Ford D, Mathur R, Chaturvedi N, Kaplan R, Smeeth L, Bhaskaran K (2019) Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models. Int J Epidemiol. 48(2):527–537. https://doi.org/10.1093/ije/dyz005CrossRefPubMedPubMedCentral

33.

Bodmer M, Becker C, Meier C, Jick SS, Meier CR (2012) Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 21(2):280–286. https://doi.org/10.1158/1055-9965.EPI-11-0992-TCrossRefPubMed

34.

Dankner R, Agay N, Olmer L, Murad H, Keinan Boker L, Balicer RD, Freedman LS (2019) Metformin Treatment and Cancer Risk: Cox Regression Analysis, With Time-Dependent Covariates, of 320,000 Persons With Incident Diabetes Mellitus. Am J Epidemiol. 188(10):1794–1800. https://doi.org/10.1093/aje/kwz157CrossRefPubMedPubMedCentral

35.

Murff HJ, Roumie CL, Greevy RA, Hackstadt AJ, McGowan LED, Hung AM et al (2018) Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer. Cancer Causes Control. 29(9):823–832. https://doi.org/10.1007/s10552-018-1058-4CrossRefPubMedPubMedCentral

36.

Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH et al (2012) Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 35(1):119–124. https://doi.org/10.2337/dc11-0857CrossRefPubMed

37.

Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M (2011) Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care. 34(9):1965–1971. https://doi.org/10.2337/dc11-0699CrossRefPubMedPubMedCentral

38.

de Jong RG, Burden AM, de Kort S, van Herk-Sukel MP, Vissers PA, Janssen PK, Haak HR, Masclee AA, de Vries F, Janssen-Heijnen ML (2017) No Decreased Risk of Gastrointestinal Cancers in Users of Metformin in The Netherlands; A Time-Varying Analysis of Metformin Exposure. Cancer Prev Res (Phila). 10(5):290–297. https://doi.org/10.1158/1940-6207.CAPR-16-0277CrossRefPubMed

39.

Vicentini M, Ballotari P, Giorgi Rossi P, Venturelli F, Sacchettini C, Greci M, Mangone L, Pezzarossi A, Manicardi V (2018) Effect of different glucose-lowering therapies on cancer incidence in type 2 diabetes: An observational population-based study. Diabetes Res Clin Pract. 143:398–408. https://doi.org/10.1016/j.diabres.2018.04.036CrossRefPubMed

40.

Oliveria SA, Koro CE, Yood MU, Sowell M (2008) Cancer incidence among patients treated with antidiabetic pharmacotherapy. 2:47—57. https://doi.org/10.1016/j.dsx.2007.11.002.

41.

Rosato V, Tavani A, Gracia-Lavedan E, Guino E, Castano-Vinyals G, Villanueva CM et al (2016) Type 2 Diabetes, Antidiabetic Medications, and Colorectal Cancer Risk: Two Case-Control Studies from Italy and Spain. Front Oncol. 6:210. https://doi.org/10.3389/fonc.2016.00210CrossRefPubMedPubMedCentral

42.

Sehdev A, Shih YC, Vekhter B, Bissonnette MB, Olopade OI, Polite BN (2015) Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer. 121(7):1071–1078. https://doi.org/10.1002/cncr.29165CrossRefPubMed

43.

Cardel M, Jensen SM, Pottegard A, Jorgensen TL, Hallas J (2014) Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study. Cancer Med. 3(5):1458–1466. https://doi.org/10.1002/cam4.306CrossRefPubMedPubMedCentral

44.

Shin CM, Kim N, Han K, Kim B, Jung JH, Oh TJ, Lee DH (2020) Anti-diabetic medications and the risk for colorectal cancer: A population-based nested case-control study. Cancer Epidemiol. 64:101658. https://doi.org/10.1016/j.canep.2019.101658CrossRefPubMed

45.

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 355(23):2427–2443. https://doi.org/10.1056/NEJMoa066224CrossRefPubMed

Title: Relationship between metformin therapy and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis
Authors: Wen-Tao Yang
Hao-Jie Yang
Jian-Guo Zhou
Jia-Le Liu
Publication date: 01-11-2020
Publisher: Springer Berlin Heidelberg
Keywords: Metformin
Colorectal Cancer
Colorectal Cancer
Published in: International Journal of Colorectal Disease / Issue 11/2020
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-020-03704-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Relationship between metformin therapy and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2020

Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis

Gender aspects of survival after abdominoperineal resection for low rectal cancer: a retrospective study

What is the impact of systemic chemotherapy for lateral lymph nodes in patients with locally advanced low rectal cancer?

Qualitative faecal immunochemical tests (FITs) for diagnosing colorectal cancer in patients with histories of rectal bleeding in primary care: a cohort study

Incidence and risk factors of postoperative ileus after hysterectomy for benign indications

Correction to: Long-term results achieved by guideline-based stage-dependent management of anal cancer in a non-HIV population